Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York City, USA.
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York City, USA.
Head Neck. 2021 Apr;43(4):1056-1062. doi: 10.1002/hed.26563. Epub 2021 Feb 19.
Proton beam radiation therapy (PBRT) has dosimetric advantages compared to photon radiation therapy for the treatment of major salivary gland tumors (MSGTs).
Patients with non-metastatic MSGTs treated at a single proton therapy center from October 2013 to October 2018 were retrospectively reviewed.
Sixty-eight patients with MSGTs were included and the most common site and histology were the parotid gland (75.0%) and adenoid cystic carcinoma (22.1%), respectively. The 3-year rates of locoregional control, progression-free survival, and overall survival were 95.1% (95% CI: 89.9%-100.0%), 80.7% (70.2%-92.7%), and 96.1% (95% CI: 90.9%-100.0%), respectively.
In a large cohort of MSGTs treated with PBRT, the rates of locoregional control were high in short-term follow-up and treatment was well tolerated.
与光子放射治疗相比，质子束放射治疗（PBRT）在治疗大涎腺肿瘤（MSGTs）方面具有剂量学优势。
回顾性分析了 2013 年 10 月至 2018 年 10 月在一家质子治疗中心治疗的非转移性 MSGT 患者。
共纳入 68 例 MSGT 患者，最常见的部位和组织学类型分别为腮腺（75.0%）和腺样囊性癌（22.1%）。3 年局部区域控制率、无进展生存率和总生存率分别为 95.1%（95%CI：89.9%-100.0%）、80.7%（70.2%-92.7%）和 96.1%（95%CI：90.9%-100.0%）。
在接受 PBRT 治疗的 MSGT 大队列中，短期随访的局部区域控制率较高，且治疗耐受性良好。
